<DOC>
	<DOCNO>NCT00670306</DOCNO>
	<brief_summary>Benign Prostatic Hyperplasia ( BPH ) common hyperplastic disease occur human male age 50 increase prevalence age 40 % male report moderate severe urinary symptom prostatism age 50 80 . The purpose study collect safety efficacy data dosage regimen cetrorelix pamoate . For study , study medication ( Cetrorelix pamoate ) administer injection buttock ( Intramuscular ) .</brief_summary>
	<brief_title>Cetrorelix Pamoate IM Regimens Patients With Symptomatic Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<criteria>Benign Prostatic Hyperplasia , base medical history Voiding symptom Uroflow ( max ) 515mL/sec Urgent need prostate surgery History allergic reaction peptide Major organ dysfunction Prior surgical treatment prostate bladder Current recent treatment sexual hormone drug 5 α reductase inhibitor botulinum toxin type ( Botox ) within last 6 month prior trial medication Week 0 α blocker saw palmetto within last 6 week prior trial medication Week 0 Urologic disorder include neurogenic bladder dysfunction due diabetes mellitus document neurologic disorder , urethral stricture disease history pelvic radiation therapy History acute obstructive , infectious , neurological disorder genitourinary tract within last 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Cetrorelix</keyword>
	<keyword>BPH</keyword>
</DOC>